This week PharmaShots’ news was all about the updates on Clinical Trials, Pharma, Regulatory & M&A. Check out our full report below:

Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

Read More: Biogen                                                                                                

Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)

Read More: Novartis      

Shuttle Pharma Reports the Completion of Clinical Trial Site Enrollment for the P-II Study of Ropidoxuridine for Glioblastoma

Read More: Shuttle Pharma

EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)                                                                                             

Read More: EyePoint Pharmaceuticals

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Read More: Rallybio

Modalis Therapeutics’ MDL-101 Gains the US FDA’s Orphan Drug Designation to Treat Congenital Muscular Dystrophy Type 1A (LAMA2-CMD)

Read More: Modalis Therapeutics

European Patent Office (EPO) Grants Approval to Biogen’s Tecfidera Patent

Read More: Biogen

Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs

Read More: Iterum Therapeutics

Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD

Read More: Kind Pharmaceutical

AstraZeneca’s Fasenra Receives EU Approval for Eosinophilic Granulomatosis with Polyangiitis

Read More: AstraZeneca

The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase

Read More: Novartis

Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications

Read More: Shorla Oncology

Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individuals

Read More: Johnson & Johnson

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

Read More: Astellas

Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)

Read More: Monte Rosa Therapeutics & Novartis

Lisata Therapeutics and the University of Cincinnati Enters into Sponsored Agreement for Certepetide to Treat Endometriosis

Read More: Lisata Therapeutics and the University of Cincinnati

Biogen and Neomorph Collaborate to Discover and Develop Molecular Glue Degraders (MGD)

Read More: Biogen and Neomorph

GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline

Read More: GSK and Chimagen Biosciences